
Please try another search
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review